Retrospective analysis of own long-term experience in studying the BCR::ABL kinase domain mutational status in patients with chronic myeloid leukemia

Retrospective analysis of own long-term experience in studying the BCR::ABL kinase domain mutational status in patients with chronic myeloid leukemia

Background. Most patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors achieve durable optimal responses. Loss of the achieved molecular response is observed in 15–30 % of patients. Mutations in the BCR::ABL kinase domain are one of the most common mechanisms for the d...

Full description

Saved in:
Bibliographic Details
Main Authors: D. V. Kustova, E. V. Motyko, A. N. Kirienko, T. N. Gert, I. V. Leppyanen, M. P. Bakay, E. V. Efremova, E. V. Morozova, E. G. Lomaia, V. A. Shuvaev, S. V. Sidorkevich, I. S. Martynkevich
Format: Article
Language:Russian
Published: ABV-press 2024-09-01
Series:Онкогематология
Subjects:
chronic myeloid leukemia
mutation
additional chromosomal aberrations
therapy with tyrosine kinase inhibitors
resistance to targeted therapy
variant translocation t(9
22)
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/936
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://oncohematology.abvpress.ru/ongm/article/view/936

Similar Items